EXECUTIVE SUMMARY

i.       Clinical Issues in Wound Management

ii.       Skin Replacements and Substitutes

a.   Allografts

b.   Autografts

c.   Xenografts

d.   Amniotic Membranes

e.   Skin Equivalents

f.    Skin Replacements and Substitutes, Market Analysis

iii.      Active Wound Repair Modulators

a.   Topical Antimicrobial Products

b.   Growth Factors

c.   Other Active Wound Repair Modulators

d.   Active Wound Repair Modulators, Market Analysis

iv.      Combined Market Analysis

a.   Market Drivers

b.   Market Limiters

c.   Combined Market Forecast

 

Exhibit ES-1:    Europe, Skin Replacements and Substitutes, Market Forecast, by Country, 2008-2013

Exhibit ES-2:    Europe, Active Wound Repair Modulators, Market Forecast, by Country, 2008-2013

Exhibit ES-3:    Europe, Skin Replacements and Substitutes and Active Wound Repair Modulators, Combined Market Forecast, by Country, 2008-2013

 

1. EUROPEAN HEALTHCARE MARKETS

1.1 The European Union

1.1.1 A Common Currency

1.1.2 Regulatory Policies

1.1.3 Reimbursement

1.1.4 Healthcare Spending

1.2 Selected European National Healthcare Profiles

1.2.1 France

1.2.1.1 Healthcare Organization and Reform

1.2.1.2 Hospital Services

1.2.1.3 Medical Device Reimbursement

1.2.2 Germany

1.2.2.1 Healthcare Organization and Reform

1.2.2.2 Hospital Services

1.2.2.3 Medical Device Reimbursement

1.2.3 Italy

1.2.3.1 Healthcare Organization and Reform

1.2.3.2 Hospital Services

1.2.3.3 Medical Device Reimbursement

1.2.4 Spain

1.2.4.1 Healthcare Organization and Reform

1.2.4.2 Hospital Services

1.2.4.3 Medical Device Reimbursement

1.2.5 United Kingdom

1.2.5.1 Healthcare Organization and Reform

1.2.5.2 Hospital Services

1.2.5.3 Medical Device Reimbursement

 

Exhibit 1-1:      European Union, Medical Devices Risk Classification System

Exhibit 1-2:      European Union Population Statistics Comparison for the Years 1999, 2009, and 2019

Exhibit 1-3:      France, Selected National Healthcare Statistics

Exhibit 1-4:      Germany, Selected National Healthcare Statistics

Exhibit 1-5:      Italy, Selected National Healthcare Statistics

Exhibit 1-6:      Spain, Selected National Healthcare Statistics

Exhibit 1-7:      United Kingdom, Selected National Healthcare Statistics

 

2. CLINICAL ISSUES IN WOUND MANAGEMENT

2.1 Physiology of Wound Closure

2.1.1 Layers of the Skin and Supporting Structures

2.1.1.1 Epidermis

2.1.1.2 Dermis

2.1.1.3 Subcutaneous Tissue

2.1.1.4 Fascia

2.1.1.5 Muscle

2.1.1.6 Bone

2.1.2 Wound Closure Process

2.1.2.1 Hemostasis

2.1.2.2 Inflammation

2.1.2.3 Proliferation

2.1.2.4 Remodeling Phase

2.2 Factors Affecting Wound Closure

2.2.1 Extrinsic Factors

2.2.1.1 Desiccation

2.2.1.2 Hydration

2.2.1.3 Infection

2.2.1.4 Maceration

2.2.1.5 Medication and Other Treatment Modalities

2.2.1.6 Necrotic Tissue and Debris

2.2.1.7 Oxygenation

2.2.1.8 Stress

2.2.1.9 Temperature

2.2.1.10 Wound Creation and Depth

2.2.1.11 Wound Closure Techniques

2.2.1.12 Other Extrinsic Factors

2.2.2 Intrinsic Factors

2.2.2.1 Body Build

2.2.2.2 Chronic Illness and Age

2.2.2.3 Nutrition

2.2.3 Complications of Wound Healing

2.2.3.1 Bleeding

2.2.3.2 Scarring

2.3 Major Wound Types

2.3.1 Amputation

2.3.2 Arterial Ulcers

2.3.3 Burns

2.3.4 Diabetic Ulcers

2.3.5 Pressure Ulcers

2.3.6 Surgical Wounds

2.3.7 Traumatic Wounds

2.3.8 Venous Ulcers

 

Exhibit 2-1:      The Skin’s Layers and Supporting Structures

Exhibit 2-2:      Phases of the Wound Closure Process

Exhibit 2-3:      Extrinsic and Intrinsic Factors Affecting Wound Closure

Exhibit 2-4:      Major Wound Types, by Cause

Exhibit 2-5:      Stages of Burn Wounds

Exhibit 2-6:      Stages of Pressure Ulcers

Exhibit 2-7:      2008, Europe, Surgical Procedure Volumes, by Type

 

3. SKIN REPLACEMENTS AND SUBSTITUTES MARKET

3.1 Allografts

3.2 Autografts

3.3 Xenografts

3.4 Amniotic Membranes

3.5 Autologous and Tissue-Engineered Skin Replacements and Substitutes

3.5.1 Epidermal Equivalents

3.5.2 Dermal Equivalents

3.5.3 Composite Bilayer Skin Equivalents

3.6 Skin Substitute Products under Development

3.6.1 Advanced BioHealing

3.6.2 Healthpoint/DFB Pharmaceuticals

3.6.3 Organogenesis

3.6.4 Dr. Suwelack Skin & Health Care

3.7 Market Analysis

3.8 Competitive Analysis

 

Exhibit 3-1:      Advantages and Disadvantages of Allografts

Exhibit 3-2:      2010, Selected Epidermal Equivalent Skin Substitutes

Exhibit 3-3:      2010, Selected Dermal Equivalent Skin Substitutes

Exhibit 3-4:      2010, Selected Composite Bilayer Equivalent Skin Substitutes

Exhibit 3-5:      Europe, Skin Replacements and Substitutes, Market Forecast, by Country, 2008-2013

Exhibit 3-6:      2009, Europe, Skin Replacements and Substitutes Market, Share by Supplier

 

4. ACTIVE WOUND REPAIR MODULATORS MARKET

4.1 Topical Antimicrobials

4.1.1 Products

4.1.2 Market Analysis

4.1.3 Competitive Analysis

4.2 Growth Factors

4.2.1 Classification of Growth Factors

4.2.1.1 Fibroblast Growth Factors

4.2.1.2 Transforming Growth Factors

4.2.1.3 Epidermal Growth Factors

4.2.1.4 Platelet-Derived Growth Factors

4.2.1.5 Insulin-Like Growth Factors

4.2.1.6 Keratinocyte Growth Factors

4.2.1.7 Vascular Endothelial Growth Factors

4.2.1.8 Autologous Growth Factors

4.2.1.8.1 Arteriocyte Medical Systems

4.2.1.8.2 Cytomedix

4.2.1.8.3 Harvest Technologies

4.2.1.9 Angiogenic Growth Factors

4.2.2 Products

4.2.3 Market Analysis

4.3 Gene Therapy Agents

4.4 Other Active Wound Repair Modulators

4.4.1 Antibiotics and Anti-Infectives

4.4.1.1 Basilea Pharmaceutica

4.4.1.2 Cerexa/Forest Laboratories

4.4.1.3 Cubist Pharmaceuticals

4.4.1.4 Helix BioMedix

4.4.1.5 Theravance

4.4.2 Hormones

4.4.3 Matrix Metalloproteinase Enzyme Inhibitors

4.4.3.1 Dermagenics/Greystone Pharmaceuticals

4.4.3.2 Smith & Nephew

4.4.3.3 Systagenix Wound Management

4.4.4 Neuropeptides in Diabetic Wounds

4.4.5 Stem Cells

4.4.6 Other Products

4.4.6.1 Kingfisher Healthcare

4.4.6.2 Pioneer Surgical Orthobiologics/Pioneer Surgical Technology

4.4.6.3 RegeneRx Biopharmaceuticals

 

Exhibit 4-1:      2010, Selected Topical Antimicrobial Products

Exhibit 4-2:      Europe, Topical Antimicrobial Products, Market Forecast, by Country, 2008-2013

Exhibit 4-3:      2009, Europe, Topical Antimicrobial Products, Share by Supplier

Exhibit 4-4:      2010, Selected Growth Factors in Development for Wound Healing Applications

Exhibit 4-5:      2010, Selected Angiogenic Growth Factors

Exhibit 4-6:      Europe, Growth Factors Used in Wound Healing Applications, Market Forecast,  by Country, 2008-2013

 

5. COMPANY PROFILES

5.1       Advanced BioHealing, Inc.

5.2       Cook Biotech, Inc./Cook Group, Inc.

5.3       Cytomedix, Inc.

5.4       Fidia Advanced Biopolymers SRL/Anika Therapeutics, Inc.

5.5       GlaxoSmithKline PLC

5.6       Integra LifeSciences Corporation

5.7       LEO Pharma AS/LEO Foundation

5.8       sanofi-aventis

5.9       Smith & Nephew PLC

5.10     Systagenix Wound Management LTD

 

APPENDIX: COMPANY LISTING